Neurocrine Biosciences Market Sentiment

SPY733.43−4.35%QQQ648.01−6.35%BTC/USD75,899.99−5.63%DIA514.68−3.46%GLD375.29+0.75%TLT81.97+0.25%

Premium Services

Neurocrine Biosciences Inc

NBIXNASDAQ

Trade with Public

$159.90

-6.15-3.7%

Last update: Nov 5, 3:59 PM

Overview News Earnings Forecast Events Price Targets FinancialsSentimentOwnership Compare Options Stock Report

Earnings: Q3 2026 Earnings were released on Mon Nov 2nd, after the market close

Conference Call: The most recent conference call started at 4:30 PM, 3 days ago

Click to view the webcast

Neurocrine Biosciences Market Sentiment - Benzinga

Neurocrine Biosciences Market Sentiment

Market sentiment signals for Neurocrine Biosciences (NBIX): analyst consensus, short interest, options flow and insider activity.

Key Signals

Analyst Consensus▲ Buy

Short Interest▼ 8.3% short float

Options Flow▲ 0.79 P/C ratio

Insider Activity— Neutral (30d)

Analyst Consensus

Buy

25 analysts

Options Flow (P/C)

0.79

More calls — Bullish

48 calls · 38 puts

Avg Consensus PT

$202

+26.6%

Highest Price Target

$253

+58.2%

Citigroup

Lowest Price Target

$150

-6.2%

BMO Capital

Short Interest

8.3%

Rising — Bearish

Insider Activity (30d)

Neutral

Short Interest — % of Float

Recent Analyst Actions

Date	Firm	Analyst & Accuracy	Upside / Downside	PT Change	Action	Rating
Nov 4, 2026	Guggenheim	Delma Caiati—	+40.1%	$207 → $224	Maintained	Buy
Nov 3, 2026	Piper Sandler	David Amsellem—	+34.5%	$210 → $215	Maintained	Overweight
Nov 3, 2026	Morgan Stanley	Jeffrey Hung—	+15.7%	$183 → $185	Maintained	Equal-Weight
Nov 3, 2026	RBC Capital	Brian Abrahams—	+18.8%	$187 → $190	Maintained	Outperform
Nov 3, 2026	Canaccord Genuity	Sumant Kulkarni—	+37.6%	$210 → $220	Maintained	Buy
Oct 16, 2026	Needham	Ami Fadia—	+27.6%	$204 → $204	Maintained	Buy
Oct 12, 2026	BMO Capital	Evan Seigerman—	-6.2%	$164 → $150	Maintained	Market Perform
Oct 6, 2026	Guggenheim	Delma Caiati—	+29.5%	$207	Assumes	Buy
Sep 29, 2026	UBS	Ashwani Verma—	+33.8%	$231 → $214	Maintained	Buy
Sep 11, 2026	Morgan Stanley	Jeffrey Hung—	+14.4%	$182 → $183	Maintained	Equal-Weight
Sep 8, 2026	RBC Capital	Brian Abrahams—	+23.8%	$198 → $198	Maintained	Outperform
Sep 3, 2026	Citigroup	Yigal Nochomovitz—	+58.2%	$249 → $253	Maintained	Buy
Aug 13, 2026	Morgan Stanley	Jeffrey Hung—	+13.8%	$196 → $182	Maintained	Equal-Weight
Aug 3, 2026	Canaccord Genuity	Sumant Kulkarni—	+31.3%	$200 → $210	Maintained	Buy
Aug 3, 2026	Truist Securities	Danielle Brill—	+33.2%	$200 → $213	Maintained	Buy
Aug 3, 2026	Wedbush	Laura Chico—	+21.3%	$185 → $194	Maintained	Outperform
Jul 31, 2026	Citigroup	Yigal Nochomovitz—	+55.7%	$246 → $249	Maintained	Buy
Jul 31, 2026	RBC Capital	Brian Abrahams—	+23.8%	$195 → $198	Maintained	Outperform
Jul 31, 2026	Morgan Stanley	Jeffrey Hung—	+22.6%	$193 → $196	Maintained	Equal-Weight
Jul 31, 2026	TD Cowen	Phil Nadeau—	+37.6%	$200 → $220	Maintained	Buy
Jul 31, 2026	Piper Sandler	David Amsellem—	+31.3%	$207 → $210	Maintained	Overweight
Jul 31, 2026	Cantor Fitzgerald	Josh Schimmer—	+34.5%	$210 → $215	Maintained	Overweight
Jul 31, 2026	Guggenheim	Yatin Suneja—	+38.8%	$200 → $222	Maintained	Buy
Jul 31, 2026	Stifel	Paul Matteis—	+34.5%	$188 → $215	Maintained	Buy
Jul 31, 2026	Needham	Ami Fadia—	+27.6%	$200 → $204	Maintained	Buy